TCGA-D8-A1X6-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.540
- MYC_TARGETS_V1+0.480
- E2F_TARGETS+0.390
- DNA_REPAIR+0.380
- INTERFERON_ALPHA_RESPONSE+0.360
- MYC_TARGETS_V2+0.340
- FATTY_ACID_METABOLISM+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.260
- G2M_CHECKPOINT+0.240
- ADIPOGENESIS+0.170
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ANGIOGENESIS-0.400
- TGF_BETA_SIGNALING-0.360
- MYOGENESIS-0.330
- UV_RESPONSE_DN-0.330
- CHOLESTEROL_HOMEOSTASIS-0.310
- COAGULATION-0.300
- NOTCH_SIGNALING-0.300
- KRAS_SIGNALING_UP-0.280
- APICAL_JUNCTION-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.890 |
| 2 | TCGA-66-2763-01A-01R-0851-07 | — | cohortSQ1 | 0.867 |
| 3 | 20040117.Her2HRpos | — | B | 0.858 |
| 4 | C3L-00415 | — | cohortSQ1 | 0.857 |
| 5 | SRR11296797 | — | — | 0.849 |
| 6 | SRR6013515 | — | cohortA4 | 0.849 |
| 7 | 20080227.Her2HRpos | — | C | 0.846 |
| 8 | TCGA-BA-A6DL-01A-21R-A30B-07 | — | — | 0.844 |
| 9 | MNG171 | — | — | 0.842 |
| 10 | SRR27320678 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.480 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| PEROXISOME | 0.170 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.070 | Inavolisib | — uncovered |